1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 Data Mining Process

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 Secondary Research data flow:

3.5 PRIMARY RESEARCH:

3.5.1 Primary Research DATA FLOW:

3.5.2 Primary Research: Number of Interviews conducted

3.5.3 Primary Research: Regional Coverage

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 Revenue Analysis Approach

3.7 DATA FORECASTING

3.7.1 Data forecasting Type

3.8 DATA MODELING

3.8.1 microeconomic factor analysis:

3.8.2 Data modeling:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 Growing incidences of Cancer and rare disorders

4.2.2 Increasing approval for Gene and Cell therapy Products

4.3 RESTRAINTS

4.3.1 Clinical Trial Failure associated with gene and cell therapy

4.4 OPPORTUNITY

4.4.1 Growing investment in the field of gene and cell therapy

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 Threat of New Entrants

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 Threat of Substitutes

5.1.4 Bargaining Power of Buyers

5.1.5 Intensity of Rivalry

5.2 IMPACT OF COVID-19 ON THE GLOBAL CELL AND GENE THERAPY MARKET

6 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE

6.1 OVERVIEW

6.2 CELL THERAPY

6.2.1 Autologous

6.2.2 Allogeneic

6.3 GENE THERAPY

6.3.1 Ex vivo

6.3.2 In vivo

7 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 CANCER

7.3 NEUROLOGICAL DISORDERS

7.4 CARDIOVASCULAR DISORDERS

7.5 RARE DISEASES

7.6 OPHTHALMOLOGY

7.7 BLOOD DISORDERS

7.8 OTHERS

8 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 Germany

8.3.2 France

8.3.3 UK

8.3.4 Italy

8.3.5 Spain

8.3.6 Rest of Europe

8.4 ASIA-PACIFIC

8.4.1 China

8.4.2 India

8.4.3 Japan

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-pacific

8.5 REST OF THE WORLD

8.5.1 Middle East & Africa

8.5.2 South America

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION

9.2 MARKET SHARE ANALYSIS, 2022

9.3 COMPETITOR DASHBOARD

9.4 PUBLIC PLAYERS STOCK SUMMARY

9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 product launch / Product approval

9.6.2 Collaboration

9.6.3 Agreement

9.6.4 Expansion

10 COMPANY PROFILES

10.1 NOVARTIS AG

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 products OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 BRISTOL-MYERS SQUIBB COMPANY

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 products OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 AMGEN INC.

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 productS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 AURION BIOTECH

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 productS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 SAREPTA THERAPEUTICS, INC.

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 productS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 FERRING B.V.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 products OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SIBIONO GENETECH CO. LTD., SHENZHEN (SIBIONO)

10.7.1 COMPANY OVERVIEW

10.7.2 products OFFERED

10.7.3 KEY DEVELOPMENTS

10.7.4 KEY STRATEGIES

10.8 BLUEBIRD BIO, INC.

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 SWOT Analysis

10.8.6 KEY STRATEGIES

10.9 KITE PHARMACEUTICALS, INC.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 SWOT Analysis

10.9.6 KEY STRATEGIES

10.10 JANSSEN GLOBAL SERVICES

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 Products OFFERed

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES